Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia
Abstract Background Definite prognostic clinical factors of benefit for decitabine-based induction chemotherapy in elderly patients newly diagnosed with acute myeloid leukaemia (AML) are not identified. This study was designed to explore the potential biomarker, especially regeneration of haematopoi...
Main Authors: | Jiayu Huang, Huihui Zhao, Ming Hong, Han Zhu, Yu Zhu, Yun Lian, Shan Li, Jianyong Li, Sixuan Qian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-5160-5 |
Similar Items
-
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
by: Miriam Saiz-Rodríguez, et al.
Published: (2021-11-01) -
Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01) -
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
by: Yi Li, et al.
Published: (2024-01-01) -
An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia
by: Lisa Repsold, et al.
Published: (2017-10-01) -
Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
by: Jun-Feng Zhu, et al.
Published: (2022-10-01)